<DOC>
	<DOCNO>NCT00620516</DOCNO>
	<brief_summary>This descriptive observational open non-comparative study safety efficacy tiotropium inhalation capsule give 18mcg day 30 day among Korean patient COPD . At Visit 1 , patient diagnose COPD prescribe tiotropium inhalation capsule 18mcg daily ( time ) . Patients ' FEV1 assess start treatment ( Visit 1 ) end 30 day treatment period ( Visit 2 ) . Occurrence adverse event also ask patient end 30 day treatment period . Patients inform attend physician immediately report occurrence serious adverse event .</brief_summary>
	<brief_title>Tiotropium 18ug Inhalation Capsule Using HandihalerÂ® Among Korean COPD Patients</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Older 40 year old Diagnosed COPD No Previous Spiriva administration No Contraindication Spiriva accord product label patient history hypersensitivity atropine derivative ( e.g . ipratropium oxitropium component product ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>